Faaborg Louise, Jakobsen Anders, Waldstrøm Marianne, Petersen Christina B, Andersen Rikke F, Steffensen Karina D
Department of Oncology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, 7100, Denmark.
Institute of Regional Health Research, University of Southern Denmark, Odense, 5000, Denmark.
Biomark Med. 2021 Oct;15(15):1309-1317. doi: 10.2217/bmm-2021-0144. Epub 2021 Sep 13.
In ovarian cancer, methylated HOXA9 (meth-HOXA9) has been proposed as a relevant biomarker, however, its role in the carcinogenic development remains unknown. This study aimed at evaluating meth-HOXA9 as a diagnostic biomarker in ovarian cancer. The meth-HOXA9 status was examined in 138 tissue specimens encompassing normal ovaries, benign- and borderline tumors, and ovarian cancer using droplet digital PCR. Meth-HOXA9 was detected in 93% (82/88) and 88% (14/16) of ovarian cancer and borderline tumors, respectively. In patients with benign ovarian tumors meth-HOXA9 was detected in 17% (3/18). Using receiver operating characteristic (ROC) analysis meth-HOXA9 had a diagnostic accuracy of 98%. Meth-HOXA9 is highly cancer specific and could serve as a general diagnostic marker of ovarian malignancy.
在卵巢癌中，甲基化的HOXA9（meth-HOXA9）被认为是一种相关生物标志物，然而，其在致癌发展中的作用仍不清楚。本研究旨在评估meth-HOXA9作为卵巢癌诊断生物标志物的价值。使用液滴数字PCR检测了138份组织标本中的meth-HOXA9状态，这些标本包括正常卵巢、良性和交界性肿瘤以及卵巢癌。meth-HOXA9分别在93%（82/88）的卵巢癌和88%（14/16）的交界性肿瘤中被检测到。在良性卵巢肿瘤患者中，17%（3/18）检测到meth-HOXA9。使用受试者工作特征（ROC）分析，meth-HOXA9的诊断准确率为98%。meth-HOXA9具有高度的癌症特异性，可作为卵巢恶性肿瘤的通用诊断标志物。
